Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Bayer HealthCare’s rivaroxaban shows efficacy in stroke prevention

Bayer HealthCare’s rivaroxaban shows efficacy in stroke prevention

26th May 2011

Bayer HealthCare has published new data on its atrial fibrillation (AF) drug rivaroxaban that shows its effectiveness in preventing strokes.

A pre-planned subgroup analysis has been conducted for the Rocket AF phase III clinical trial to assess the performance of the developmental drug among AF patients who have experienced a prior stroke or transient ischemic attack.

It was found to outperform warfarin, the current standard of care, in reducing the risk of stroke and systemic embolism among this group.

This could be a potentially significant discovery, as clinicians are currently reliant on warfarin to prevent AF-related stroke, despite the well-known side effects associated with the drug.

Professor Werner Hacke, chair of the department of neurology at the University of Heidelberg, said: "The Rocket AF study has given us a unique opportunity to compare existing care with a new-generation medicine that does not have the same limitations as warfarin."

At the American Society of Clinical Oncology (ASCO) annual meeting on the 3rd of June, the company will present data on compounds, including Alpharadin.ADNFCR-8000103-ID-800557669-ADNFCR

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.